GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neuraxis Inc (AMEX:NRXS) » Definitions » Price-to-Owner-Earnings

Neuraxis (Neuraxis) Price-to-Owner-Earnings : (As of Jun. 20, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Neuraxis Price-to-Owner-Earnings?

As of today (2024-06-20), Neuraxis's share price is $2.70. Neuraxis does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Neuraxis's Price-to-Owner-Earnings or its related term are showing as below:


NRXS's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.555
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-20), Neuraxis's share price is $2.70. Neuraxis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.89. Therefore, Neuraxis's PE Ratio for today is At Loss.

As of today (2024-06-20), Neuraxis's share price is $2.70. Neuraxis's EPS without NRI for the trailing twelve months (TTM) ended in was $-2.16. Therefore, Neuraxis's PE Ratio without NRI for today is At Loss.


Neuraxis Price-to-Owner-Earnings Historical Data

The historical data trend for Neuraxis's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neuraxis Price-to-Owner-Earnings Chart

Neuraxis Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
- - - -

Neuraxis Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Neuraxis's Price-to-Owner-Earnings

For the Biotechnology subindustry, Neuraxis's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neuraxis's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuraxis's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Neuraxis's Price-to-Owner-Earnings falls into.



Neuraxis Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Neuraxis's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.70/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neuraxis  (AMEX:NRXS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Neuraxis Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Neuraxis's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Neuraxis (Neuraxis) Business Description

Traded in Other Exchanges
N/A
Address
11550 N. Meridian Street, Suite 325, Carmel, IN, USA
Neuraxis Inc is a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.
Executives
Masimo Corp 10 percent owner 52 DISCOVERY, IRVINE CA 92618
John G Seale officer: CHIEF FINANCIAL OFFICER 10038 OXFORD PIKE, BROOKVILLE IN 47012
Brian Allen Carrico director, officer: CEO, DIRECTOR 11550 NORTH MERIDIAN STREET, SUITE 325, CARMEL IN 46032
Christopher Robin Brown director, officer: DIRECTOR OF INNOVATION 829 S. ADAMS ST, VERSAILLES IN 47042
Daniel Jerome Clarence officer: CHIEF OPERATING OFFICER 10461 W GRANDVIEW DRIVE, COLUMBUS IN 47201
Thomas Joeseph Carrico officer: CHIEF REGULATORY OFFICER 829 S. ADAMS ST., VERSAILLES IN 47042
Gary Merril Peterson officer: DIR.OF DESIGN & ENGINEERING 829 S. ADAMS ST., VERSAILLES IN 47042
Bradley Mitchell Watkins director 10322 MEDICIS PLACE, WELLINGTON FL 33449
Jane Elizabeth Keyser director 220 VIRGINIA AVENUE, INDIANAPOLIS IN 46204
Timothy Robert Henrichs director 324 LEITCH AVENUE, LA GRANGE IL 60525
Adrian Miranda officer: Chief Medical Officer, SVP 829 S. ADAMS STREET, VERSAILLES IN 47042